June 29, 2023 Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
Sept 28, 2022 Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis
Sept 8, 2022 Alumis Appoints Jörn Drappa M.D., Ph.D., as Chief Medical Officer and Roman G. Rubio, M.D., as Senior Vice President, Clinical Development and Translational Medicine
More News
Media Contact
Maura Gavaghan Red House Communications maura@redhousecomms.com
